The Phosphodiesterase Type 4 Inhibitor, Rolipram, Enhances Glucocorticoid Receptor Function

Author： Miller A.H.   Vogt G.J.   Pearce B.D.  

Publisher： Elsevier

ISSN： 0893-133X

Source： Neuropsychopharmacology, Vol.27, Iss.6, 2002-12, pp. : 939-948

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor- synthesis

By Greten T.F.   Sinha B.   Haslberger C.   Eigler A.   Endres S.  

European Journal of Pharmacology, Vol. 299, Iss. 1, 1996-03 ,pp. : 229-233

Elsevier

Access to resources Recommend Favorite

Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis

By Francischi J.N.   Yokoro C.M.   Poole S.   Tafuri W.L.   Cunha F.Q.   Teixeira M.M.  

European Journal of Pharmacology, Vol. 399, Iss. 2, 2000-07 ,pp. : 243-249

Elsevier

Access to resources Recommend Favorite

Phosphodiesterase type 4 that regulates cAMP level in cortical neurons shows high sensitivity to rolipram

By Yamashita N.   Yamauchi M.   Baba J.   Sawa A.  

European Journal of Pharmacology, Vol. 337, Iss. 1, 1997-10 ,pp. : 95-102

Elsevier

Access to resources Recommend Favorite

A novel phosphodiesterase 4 inhibitor template

By  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 6, 2003-06 ,pp. : 929-933

Informa Healthcare

Access to resources Recommend Favorite

Prevention of methamphetamine-induced behavioral sensitization in rats by a cyclic AMP phosphodiesterase inhibitor, rolipram

By Iyo M.   Ying B.   Hashimoto K.   Inada T.   Fukui S.  

European Journal of Pharmacology, Vol. 312, Iss. 2, 1996-09 ,pp. : 163-170

Elsevier

Access to resources Recommend Favorite